Abbvie earnings were $5.1B for the trailing 12 months ending Sep 30, 2024, with -21.3% growth year over year. The latest ABBV earnings report on Sep 30, 2024 announced Q3 2024 earnings of $1.6B, up 13.9% from last quarter. For the last reported fiscal year 2023 ending Dec 31, 2023, ABBV reported annual earnings of $4.9B, with -58.9% growth.
ABBV past earnings growth
How has ABBV's earnings growth performed historically?
On ABBV's earnings call on Invalid Date, Abbvie (NYSE: ABBV) reported Q3 2024 earnings per share (EPS) of $0.88, up 12% year over year. Total ABBV earnings for the quarter were $1.56 billion. In the same quarter last year, Abbvie's earnings per share (EPS) was $1.00.
As of the last Abbvie earnings report, Abbvie is currently profitable. Abbvie's net profit (also called net income) for the twelve months ending Sep 30, 2024 was $5.12 billion, a 21.37% decrease year over year.
What was ABBV's earnings growth in the past year?
As of Abbvie's earnings date in Invalid Date, Abbvie's earnings has grown -21.31% year over year. This is 28.95 percentage points lower than the US Drug Manufacturers - General industry earnings growth rate of 7.64%. ABBV earnings in the past year totalled $5.12 billion.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.